Edition:
United States

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

25.68USD
15 Nov 2018
Change (% chg)

-- (--)
Prev Close
$25.68
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
15,589
52-wk High
$39.67
52-wk Low
$22.23

Summary

Name Age Since Current Position

David Chiswell

64 2016 Independent Chairman of the Board

Ronald Cooper

55 2016 President, Chief Executive Officer, Director

Simon Harford

58 2018 Chief Financial Officer, Treasurer

Jan Mattsson

53 2016 Chief Operating Officer

Martha Carter

65 2016 Chief Regulatory Officer

Patrick Horn

63 2018 Chief Medical Officer

Anne Klibanski

67 2018 Director

Stephanie Okey

58 2018 Director

Michael Gutch

52 2016 Independent Director

Roger Jeffs

56 2017 Independent Director

Davey Scoon

71 2017 Independent Director

Biographies

Name Description

David Chiswell

Dr. David Chiswell, Ph.D., is the Independent Chairman of the Board of Albireo Pharma Inc, since the completion of the Biodel Transaction in November 2016. Dr. Chiswell has served as the Chairman of Albireo’s board of directors since February 2008. In 1990, Dr. Chiswell co-founded Cambridge Antibody Technology (CAT), an early innovator in the development of antibody drugs, where he was responsible for operational management from 1990 to 2002 and was Chief Executive Officer from 1996 to 2002. For his contributions to the British biotech community, Dr. Chiswell was awarded the Order of the British Empire in 2006. Dr. Chiswell earned his Ph.D. in Virology from the University of Glasgow and his B.Sc. in Microbiology from the Queen Mary College University of London. Since 2002, Dr. Chiswell has focused on the development of early stage biotechnology companies, including serving as Chief Executive Officer of Nabriva Therapeutics AG, now a publicly traded biotechnology company, from April 2009 to May 2012, and as a member of its board of directors from 2006 until August 2016. Dr. Chiswell currently serves as the CEO of Kymab Ltd., a UK-based therapeutic antibody company. Dr. Chiswell’s qualifications to serve on our board of directors include his substantial experience as chief executive officer and director of other biotechnology companies.

Ronald Cooper

Mr. Ronald Harold Wilfred Cooper is the President, Chief Executive Officer, Director of Albireo Pharma Inc. Mr. Cooper has served as Albireo’s President and Chief Executive Officer since July 2015, and has served as a member of the board of directors of Albireo since September 2015. Prior to joining Albireo, Mr. Cooper worked for over 25 years in successive leadership roles at Bristol-Myers Squibb Company, a global biopharmaceutical company. Most recently, at Bristol-Myers Squibb Company, Mr. Cooper served as President, Europe from May 2010 until November 2015; President, Northern and Central Europe from April 2009 until April 2010; and Senior Vice President and General Manager, EU Markets from January 2008 until March 2009. Previously, Mr. Cooper held multiple senior roles in the U.S. and other countries. Mr. Cooper has served on the board of directors of Genocea Biosciences, Inc., a publicly traded biopharmaceutical company, since June 2016. Mr. Cooper earned his Bachelor’s degree in Chemistry and Business Administration from St. Francis Xavier University in Canada. Mr. Cooper’s qualifications to serve on the Company’s board of directors include his extensive executive leadership and experience in the life sciences industry and his knowledge of the Company’s business as its President and Chief Executive Officer.

Simon Harford

Mr. Simon N.R. Harford is Chief Financial Officer, Treasurer of the Company. He has served as Senior Vice President and Chief Financial Officer at PAREXEL International Corporation, a global clinical research organization, from May 2017 to October 2018. Prior to that, he served in several leadership roles at GlaxoSmithKline plc, a global healthcare company (“GSK”), including serving as Senior Vice President, Finance, Global Pharmaceuticals from March 2015 to April 2017, Senior Vice President, Finance, Europe and Emerging Markets from March 2014 to February 2015, and Senior Vice President, Finance, Emerging Markets from June 2009 to February 2014. Prior to joining GSK, Mr. Harford served as Group Vice President and Controller for Avon Products, Inc., a beauty products company. Additionally, he spent two decades with Eli Lilly and Company, a pharmaceutical company, in various international leadership roles, including as Vice President and Controller. Mr. Harford received an MBA from the University of Virginia’s Darden Graduate School of Business.

Jan Mattsson

Dr. Jan P. Mattsson, Ph.D., is the Chief Operating Officer of Albireo Pharma Inc. Dr. Mattsson has served as Chief Operating Officer of Albireo since February 2010. Dr. Mattsson is a co-founder of Albireo and served as the Vice President of Operations from February 2008 to February 2010. He has served as Chief Operating Officer of Albireo AB since February 2010, and Managing Director since March 2008. He has also served as Managing Director of Elobix AB since November 2013. He has served as a director of Albireo AB since May 2008 and Elobix AB since November 2013. He served as a director of Albireo from February 2008 to April 2015. Prior to co-founding Albireo, Dr. Mattsson served as Associate Director at AstraZeneca. Dr. Mattsson holds a Bachelor’s degree in Chemistry and a Ph.D. in Biochemistry from University of Gothenburg.

Martha Carter

Ms. Martha J. Carter is the Chief Regulatory Officer of Albireo Pharma Inc, since November 2016. Ms. Carter previously served as Chief Regulatory Officer and Senior Vice President of Aegerion Pharmaceuticals, Inc. (a publicly held biopharmaceutical company) from February 2011 to July 2016. From January 2011 to February 2011, Ms. Carter served as Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics, Inc. (a privately held biopharmaceutical company), and from September 2006 to December 2010, she served as Senior Vice President, Regulatory Affairs and Quality Assurance, at Proteon. In both roles, Ms. Carter was responsible for Proteon’s worldwide regulatory and quality functions. From September 2002 to April 2006, Ms. Carter was Senior Vice President, Regulatory Affairs, for Trine Pharmaceuticals. Prior to joining Trine, Ms. Carter was Vice President, Regulatory Affairs for GelTex Pharmaceuticals, Inc. Ms. Carter holds a B.A. degree from Northeastern University.

Patrick Horn

Dr. Patrick T. Horn, M.D., Ph.D., is the Chief Medical Officer of Albireo Pharma Inc., effective August 6, 2018. He has served as Senior Vice President, Medical and Clinical Development at Orphan Technologies Ltd., a biopharmaceutical company, from January 2018 to July 2018. Prior to that, he served as Chief Medical Officer at Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, from January 2011 to December 2017. Prior to that, he served as Vice President, Clinical & Medical Affairs at Dyax Corporation, a biopharmaceutical company, from September 2007 to December 2010. Previously, Dr. Horn served in various positions at Abbott Laboratories, a pharmaceutical company, from 2001 to 2006, most recently serving as Medical Director, Head of Clinical Pharmacology. Dr. Horn received a B.S. in Chemistry from the University of Illinois, a Ph.D. in the Pharmacological and Physiological Sciences from the University of Chicago and an M.D. from the University of Chicago, Pritzker School of Medicine.

Anne Klibanski

Dr. Anne Klibanski is the Director of Albireo Pharma Inc. Dr. Klibanski is a recognized expert in the field of translational research, with a focus in rare diseases. Dr. Klibanski currently serves as the Laurie Carrol Guthart Professor of Medicine at Harvard Medical School, as Chief Academic Officer (CAO) for Partners HealthCare and as Academic Dean for Partners HealthCare at Harvard Medical School. In her role as CAO, Dr. Klibanski oversees academic programs in research and education throughout the Partners HealthCare system. Dr. Klibanski also directs the Neuroendocrine Center at Massachusetts General Hospital, where she is a practicing clinician and serves on the General Executive Committee. In addition, Dr. Klibanski is a member of the Scientific Advisory Board for Crinetics Pharmaceuticals and serves on the board of directors for Partners International. Dr. Klibanski received a B.A. from Barnard College and an M.D. from New York University School of Medicine. Dr. Klibanski’s qualifications to serve on our board of directors include her scientific background and her experience as a senior executive of a major healthcare system and a leading academic scientist, medical researcher and clinician.

Stephanie Okey

Ms. Stephanie S. Okey is the Director of Albireo Pharma Inc. Ms. Okey brings more than 25 years of experience in the biopharmaceutical industry to Albireo's board of directors. Most recently, she served as Senior Vice President, Head of North America, Rare Diseases, and U.S. General Manager, Rare Diseases, at Sanofi Genzyme. Prior to Sanofi Genzyme, Ms. Okey served in roles of increasing leadership at Genentech and Bristol-Myers Squibb. She has extensive experience in the commercialization of drug therapies, including nine rare disease therapeutics and four large-market drug therapies, with a specific focus on bringing therapeutic agents to health care providers, patients and stakeholders in a patient-centric business model. Ms. Okey holds a B.S. from Ohio State University and an M.S. from Wright State University. Ms. Okey’s qualifications to serve on our board of directors include her executive leadership experience and her extensive experience in the commercialization of orphan disease products.

Michael Gutch

Dr. Michael Gutch, Ph.D., is an Independent Director of Albireo Pharma Inc. Dr. Gutch has served as a member of our board of directors since the completion of the Biodel Transaction in November 2016 and, from October 2015 until the completion of the Biodel Transaction, he served on Albireo’s board of directors. Since April 2017, Dr. Gutch has served as the Chief Business Officer and Chief Financial Officer of Entasis Therapeutics, a biotechnology company. From January 2014 to March 2017, he served as Executive Director of Corporate Development and Head of Equities at AstraZeneca, a global biopharmaceutical company. Dr. Gutch also served as Managing Director, Medimmune Ventures, the corporate venture capital arm of AstraZeneca from September 2011 to December 2013. Dr. Gutch served as Investment Director, HIG BioVentures of the investment firm HIG Capital from February 2008 to September 2011. Dr. Gutch has previously served as a Director of numerous private biotechnology companies and nonprofit organizations. Dr. Gutch holds an MBA in Finance from Indiana University and a Ph.D. in Molecular Pathology from SUNY Stony Brook. He earned his Bachelor’s degrees in Biology and Chemistry from Alfred University. Dr. Gutch’s qualifications to serve on our board of directors include his experience as a biotechnology company executive and his experience as a venture capital investor in, and director of, several biotechnology companies.

Roger Jeffs

Dr. Roger Jeffs, Ph.D., is an Independent Director of Albireo Pharma Inc. Currently, Dr. Jeffs serves as a Senior Advisor to United Therapeutics Corporation, a biotechnology company focused in rare diseases, where he worked for 18 years, including as President and co-Chief Executive Officer. Dr. Jeffs helped guide United Therapeutics' initial public offering, managed its commercial and business development efforts, and oversaw clinical development and regulatory approval of several new drugs. Dr. Jeffs is the co-founder and co-owner of Bull City Select Investments, an investment firm focused on in-licensing and development of early-stage biotechnology assets. Previously, he served as the worldwide clinical leader of the Infectious Disease Program at Amgen Inc. and as a member of the clinical research team at Burroughs Wellcome & Company. In addition to Albireo, Dr. Jeffs is a member on the boards of directors of the public pharmaceutical companies Axsome Therapeutics, Dova Pharmaceuticals and Sangamo Therapeutics. He holds a B.A. in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine. Dr. Jeffs’ qualifications to serve on our board of directors include his scientific background and business experience, coupled with his experience as a chief executive officer of a publicly traded biotechnology company.

Davey Scoon

Mr. Davey S. Scoon is an Independent Director Albireo Pharma Inc. Mr. Scoon is the Director of Biodel Inc. Mr. Scoon’s business career has included senior executive positions in Finance and Administration across a range of industries including asset management, insurance, retailing and consumer products. His board leadership positions include board chair and audit chair positions in industries including mutual funds, health insurance and life sciences. Mr. Scoon is currently the Chair of the board of trustees for Allianz Global Investors, a board member and Audit Chair of AMAG Pharmaceuticals, Inc., and a board member of Orthofix International N.V. Previously he served as the Chairman of the audit committees of NitroMed, Inc., CardioKine, Inc. and Orthofix International N.V., and as the non-executive Chairman of Tufts Health Plan. In addition to his board work, Mr. Scoon is an adjunct professor teaching accounting at the University of Wisconsin-Madison. Mr. Scoon is an audit committee financial expert having been a Chief Financial Officer in the manufacturing, financial services and retailing industries. He has an extensive background in risk management, has operated successfully in strictly regulated industries, has been involved in M&A activities throughout his career and has a thorough working knowledge of Sarbanes Oxley. Mr. Scoon’s previous corporate experience includes Chief Administrative and Financial Officer of Tom’s of Maine, Inc., Chief Administrative and Financial Officer of Sunlife Financial U.S., Executive Vice President and Chief Operating Officer of Liberty Funds Group of Boston (formerly Colonial Management) and Certified Public Accountant with Price Waterhouse & Company. Mr. Scoon earned an MBA from Harvard Business School and a BBA in Business Administration from the University of Wisconsin.

Basic Compensation

Name Fiscal Year Total

David Chiswell

155,581

Ronald Cooper

2,476,730

Simon Harford

--

Jan Mattsson

--

Martha Carter

1,003,310

Patrick Horn

--

Anne Klibanski

--

Stephanie Okey

--

Michael Gutch

155,168

Roger Jeffs

72,878

Davey Scoon

138,081
As Of  30 Dec 2017